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Abstract
Background: Estimating the risk of malignancy is essential in the management of adnexal masses. An accurate
differential diagnosis between benign and malignant masses will reduce morbidity and costs due to unnecessary
operations, and will improve referral to a gynecologic oncologist for specialized cancer care, which improves
outcome and overall survival. The Risk of Malignancy Index is currently the most commonly used method in clinical
practice, but has a relatively low diagnostic accuracy (sensitivity 75–80 % and specificity 85–90 %). Recent reports
show that other methods, such as simple ultrasound-based rules, subjective assessment and (Diffusion Weighted)
Magnetic Resonance Imaging might be superior to the RMI in the pre-operative differentiation of adnexal masses.
Methods/Design: A prospective multicenter cohort study will be performed in the south of The Netherlands. A
total of 270 women diagnosed with at least one pelvic mass that is suspected to be of ovarian origin who will
undergo surgery, will be enrolled. We will apply the Risk of Malignancy Index with a cut-off value of 200 and a
two-step triage test consisting of simple ultrasound-based rules supplemented -if necessary- with either subjective
assessment by an expert sonographer or Magnetic Resonance Imaging with diffusion weighted sequences, to
characterize the adnexal masses. The histological diagnosis will be the reference standard. Diagnostic performances
will be expressed as sensitivity, specificity, positive and negative predictive values and likelihood ratios.
Discussion: We hypothesize that this two-step triage test, including the simple ultrasound-based rules, will have
better diagnostic accuracy than the Risk of Malignancy Index and therefore will improve the management of
women with adnexal masses. Furthermore, we expect this two-step test to be more cost-effective. If the hypothesis
is confirmed, the results of this study could have major effects on current guidelines and implementation of the
triage test in daily clinical practice could be a possibility.
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Background
Ovarian cancer is the second most common gynecologic
malignancy [1]. In 2008 it was the seventh leading cause
of cancer deaths in women worldwide [1, 2]. Estimating
the risk of malignancy is essential in the management of
adnexal masses. Patients with a malignancy should
undergo an appropriate staging procedure or debulking
surgery carried out in specialized surgical centers. This
is associated with a better median survival [3]. Vice
versa, patients with a benign lesion may be managed
conservatively or with minimal invasive surgery in non-
specialized hospitals. This will limit morbidity and avoid
unnecessary costs: laparoscopic surgery is associated
with less blood loss, shorter hospital stay, and fewer
postoperative complications with an improved quality of
life and faster return to preoperative functioning [4].
There are several methods to distinguish benign from
malignant adnexal masses. The commonly most used
method in clinical practice is the Risk of Malignancy
Index (RMI) [5–7]. The RMI is an easy to use scoring
system that is recommended by many national guide-
lines in the differential diagnosis of ovarian masses. The
RMI combines ultrasound variables, menopausal status
and serum CA125 into a score used to predict the risk
of ovarian cancer before surgery (Fig. 1). The reported
sensitivity and specificity of RMI at a cut-off value of
200 are 75–80 % and 85–90 %, respectively [8]. This re-
sults in an incorrect diagnosis (false positive or false
negative) in one out of five women with an adnexal
mass. These patients therefore receive inappropriate
treatment, potentially leading to increased morbidity
and/or mortality.
The ‘simple ultrasound-based rules’ (simple rules) is
another method to differentiate between benignity and
malignancy. This method uses different morphological
ultrasound features of adnexal masses (without including
menopausal status or serum CA125 measurement). It in-
cludes 10 rules (Table 1); five rules to predict malignancy
(M-rules) and five rules to predict a benign tumor (B-
rules). If both or none of the M- and B-rules are met the
test is inconclusive [9,10]. Simple rules are applicable in
approximately 80 % of patients with an ovarian mass
and in these cases a sensitivity of 95 % and a specificity
of 91 % is achieved in previous studies [11].
In adnexal masses for which the simple rules yield an
inconclusive result (unclassifiable masses), subjective as-
sessment by Gray-scale and color Doppler ultrasound
imaging by an experienced ultrasound examiner can be
used as a second stage test to achieve an optimal diag-
nostic performance. This subjective assessment is also
RMI RMI
I II III I II III
US score (U) Menopausal status (M) 
Multilocular                     1 1 1 Premenopausal     1 1 1
Papillary projections            1 1 1 Postmenopausal   3 4 3
Bilateral 1 1 1
Ascites                             1 1 1 CA125
Intra-abdominal metastases 1 1 1 Serum CA125 (in U/mL) …
Total …
Score 0 1 1
RMI = U x M x CA125
1 1 1
3 4 3
This figure illustrates 3 different versions of the RMI score system: RMI-I [5], RMI-II [6] and RMI-III [7]. 
These versions differ from each other in the score attributed to the ultrasound features and 
menopausal status of the patient.
Fig. 1 Schematic presentation of three different RMI score algorithms. This figure illustrates 3 different versions of the RMI score system: RMI-I [5], RMI-II
[6] and RMI-III [7]. These versions differ from each other in the score attributed to the ultrasound features and menopausal status of the patient
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called ‘pattern recognition’ [12]. The downside of sub-
jective assessment is that it is experience dependent.
Nevertheless, subjective assessment by an expert sonog-
rapher seems to be superior to any scoring system or
mathematical model when classifying adnexal masses
[10, 13, 14]. However, it is neither feasible nor efficient
that every patient would have to undergo an expert
ultrasonography. Therefore, this method is very well
suited as a second stage test. In cases where the simple
rules were inconclusive (i.e., masses that are difficult to
diagnose) subjective assessment was used successfully
with a sensitivity of 91 % and a specificity of 93 % [10].
Several individual reports have confirmed that this two-
step triage test is superior to the RMI, especially in
terms of sensitivity [15–17].
Magnetic Resonance Imaging (MRI) with diffusion
weighted sequences is another option for second stage
testing of unclassifiable masses. The use of MRI – when
interpret by specialized radiologists - also seems to be
superior to RMI in the preoperative identification of ad-
nexal masses. A meta-analysis performed by Dodge et al.
resulted in an overall sensitivity of 92 % and a specificity
of 88 % [18]. The test holds as an advantage that an
MRI can not only distinguish a benign from a malignant
mass, but can also detect possible metastases in case of
a malignancy. Furthermore, MRI can help to select pa-
tients who might be more appropriately managed by
neoadjuvant chemotherapy [19].
Objectives
The primary objective of the SUBSONiC-study (Simple
Ultrasound Based ruleS to differentiate OvariaN Cysts)
is to test the hypothesis that the simple rules, supple-
mented -in case of an inconclusive result- with either
subjective assessment by an expert sonographer or MRI,
will give better diagnostic accuracy than the RMI and
therefore will improve the management of women with
adnexal masses. Since the RMI is now widely used, any
result in favor of the triage test has the potential to alter
future clinical practice and reduce costs. Based on the
results a cost-effectiveness analysis will be performed.
Secondary objectives are to perform subgroup-analyses
for premenopausal and postmenopausal women and to
compare the diagnostic accuracy of subjective assess-
ment by an experienced ultrasound examiner with MRI
for those cases where the simple ultrasound-based rules
were inconclusive. Furthermore, the study aims to assess
various forms of interobserver-agreement: in the inter-
pretation of MRI images between radiologists; in the in-
terpretation of simple ultrasound-based rules between
the primary ultrasound and the expert ultrasound; and
in the subjective assessment between the primary ultra-
sound and the expert ultrasound. Last objective is to
perform translational research and validate new bio-
markers in the diagnosis of ovarian cancer.
Methods/Design
Study design
We will perform a prospective multicenter cohort study
in the south of The Netherlands; four regional hospitals
will participate in the study (Laurentius hospital Roer-
mond, Orbis medical center Sittard, St. Jans hospital
Weert and VieCuri Venlo) together with a tertiary refer-
ral center (Maastricht University Medical Centre +). In
total, 270 patients will be included within a timeframe of
two years. The study will end once the last patient’s final
diagnosis based on histology is known.
Study population
Female patients 18 years of age or older are eligible to
participate in the study if they are diagnosed in one of
the participating centers with at least one pelvic mass
that is suspected to be of ovarian origin, and are to
undergo surgery in order to obtain a final histological
diagnosis. Exclusion criteria are as follows: pregnancy,
age under 18 years, a prior bilateral oophorectomy, in-
sufficient or missing data, no informed consent, surgery
did not take place or takes place more than 120 days
after RMI and simple ultrasound-based rules are
performed, and/or the patient is not able or willing to
travel to the center hospital for additional diagnostic
procedures.
Table 1 Benign and malignant ultrasonic features used in
simple ultrasound-based rules as proposed by Timmerman
et al. [9]
10 Simple ultrasound-based rules
B-features (for predicting a benign tumor)
B1 Unilocular
B2 Presence of solid components, of which largest solid component
has largest diameter <7 mm
B3 Presence of acoustic shadows
B4 Smooth multilocular tumor with largest diameter <100 mm
B5 No blood flow (color score 1)
M-features (for predicting a malignant tumor)
M1 Irregular solid tumor
M2 Presence of ascites
M3 At least four papillary structures
M4 Irregular multilocular solid tumor with largest diameter ≥100 mm
M5 Very strong blood flow (color score 4)
Rule 1: If ≥ 1 M-features are present in absence of B-feature(s), the mass is
classified as malignant
Rule 2: If ≥ 1 B-features are present in absence of M-feature(s), the mass is
classified as benign
Rule 3: If both M-features and B-features are present, or if no B- or M-features
are present, the result is inconclusive and a second stage test
is recommended
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Study parameters
The primary research question is the comparison of
diagnostic test accuracy between the currently used RMI
and a new two-step triage system for the correct differ-
entiation between malignant and benign adnexal masses.
Main study parameters are sensitivity, specificity, posi-
tive predictive value, negative predictive value and posi-
tive and negative likelihood ratios. Sensitivity is defined
as the percentage of women with ovarian cancer diag-
nosed with a malignancy by the RMI and the two-step
test, respectively. The positive predictive value is defined
as the percentage of patients with a positive test result
having malignant disease. The final diagnosis will be
based on histology (gold standard).
Based on the results, a cost-effectiveness analysis will
be performed.
Study procedures
Both RMI and simple rules will be performed in the re-
gional hospitals and center hospital by general gynecolo-
gists during the same ultrasound scan. For collection of
these variables a routine transvaginal ultrasound is suffi-
cient. Transabdominal ultrasonography will be added if
the mass is too large to be seen entirely by using only
transvaginal ultrasonography. Gray scale and color Dop-
pler ultrasound live images will be used to obtain all
morphologic and blood flow variables to characterize
each mass by RMI and by simple rules. The ultrasound
will be performed by a general gynecologist or a trainee
supervised by a general gynecologist. The sonographer
will not be blinded for the serum CA125 level since this
is needed to calculate the RMI.
Only when the simple rules are inconclusive the pa-
tient will be referred to the center hospital for the sec-
ond stage tests; i.e., subjective assessment and MRI.
From previous publications it can be deducted that this
will be in approximately 20 % of patients.
Subjective assessment will be performed by an expert
ultrasound examiner. The ultrasound examiner will be a
level III sonographer according to the guidelines of the
European Federation of Societies for Ultrasound in
Medicine and Biology (EFSUMB-criteria), based on
-among others- the years of experience, the hours of
training and the total number of ultrasound scans per-
formed by the operator [20].
The MRI will be performed at 1.5 Tesla (Intera; Philips
Medical Systems, Best, The Netherlands). Conventional
2D T2-weighted sequences in three planes (sagittal, cor-
onal, axial) and 3D T1-weighted sequences in the axial
plane will be supplemented with diffusion weighted se-
quences. The MRI scans will be examined by 2 inde-
pendent radiologists with experience in MRI, and who
are blinded to the outcome of the subjective assessment.
Furthermore, a blood sample will be taken for
translational research purposes from patients with a
mass that cannot be classified by simple rules. These
serum samples will be stored for future biomarker
studies.
A secured online Case Report Form (CRF) and data-
base (‘MACRO’) are created in which the demographic
data, ultrasound data and MRI data will be stored.
Management of the mass
The RMI is currently considered the standard diagnostic
procedure. Therefore, in case of an RMI outcome of less
than 200 – i.e., when a malignancy is not suspected- the
mass is currently managed conservatively or with lapar-
oscopy. In case of an RMI outcome of 200 or more the
patient is managed together with a gynecological oncolo-
gist from the center hospital for comprehensive surgical
staging and cytoreductive (debulking) surgery, according
to prevailing guidelines.
However, it can be foreseen that conflicting results can
occur between the RMI and the simple rules combined
with the second stage test. If this is the case an individ-
ual risk assessment will be made and all conflicting re-
sults will be discussed with the patient, after which a
gynecological oncologist will be consulted when deemed
necessary. Although the RMI currently is considered
standard care, we believe that conflicting results cannot
be ignored.
Reference standard
Histopathology is the clinical reference standard used in
this study. Therefore, histology of the surgically removed
adnexal masses is necessary. The resected masses will be
classified according to the World Health Organization
guidelines for histology [21]. The pathologist will not
have access to the results of the index tests. The speci-
mens obtained for histology will be stored for 30 years,
according to prevailing guidelines from the Dutch soci-
ety for pathology [22].
Ethics and dissemination
The Medical Research Ethics Committee of the Maas-
tricht University Medical Centre in The Netherlands has
provided ethical approval for the conduct of the study.
Written informed consent will be obtained from all pa-
tients before enrollment. The results of the study will be
disseminated through international gynecological, radio-




The RMI has a relatively low sensitivity (75–80 %). By
reducing the amount of false negative test results the pa-
tient will benefit most in terms of prognosis and
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survival. For the calculation of the sample size we there-
fore focused on sensitivity as the most important pri-
mary objective.
This study is designed to have an 80 % power to detect
an increase of sensitivity from 79 % for the RMI to 91 %
for the two-step triage test with a two-sided α value of
0.05. Using a matched pair design, it can be estimated
that the total discordance between the preoperative diag-
nosis and the final diagnosis based on histology, ob-
tained by surgery, is 20 % (16 % and 4 % respectively).
Based on McNemar’s test a minimum sample size of 97
women with a malignancy is required [23]. Taking a
prevalence of malignancy of 40 % into account, the study
will need 243 patients in total. To allow for loss of
power of 10 % a total of 270 women will be enrolled in
the study.
Statistical analysis
We will use McNemar’s test to determine the statistical
significance of differences in sensitivity and specificity
between the RMI and the two-step test. For statistical
purposes borderline tumors will be classified as malig-
nant tumors. The 95 % confidence intervals for sensitiv-
ity and specificity will be obtained using Wilson’s
interval method [24].
Receiver operating characteristic (ROC) curves will be
generated using Medcalc software version 12.7.7.0
(MedCalc Software bvba, Ostend, Belgium) to illustrate
the predictive value of the chance of malignancy when
using the RMI, simple rules, subjective assessment and
MRI. The method described by DeLong et al. will be
used for the calculation of the difference between two
AUCs [25].
For the subgroup analysis of pre- and postmenopausal
women stratification will be applied.
The interobserver-agreement will be evaluated with
Cohen’s kappa (kappa values of 0.81–1.0 indicate very
good agreement, kappa values of 0.61–0.80 good agree-
ment, kappa values of 0.41–0.60 moderate agreement,
kappa values of 0.00-0.40 poor agreement) [26].
Two-tailed P-values of ≤ 0.05 will be considered statis-
tically significant for all statistical comparisons.
The economic evaluation will explore the potential
cost-effectiveness of the triage test compared to RMI. In-
cremental cost-effectiveness is expressed as difference in
the number of correct diagnosis (i.e., either true positive
or true negative for malignancy based on histology) be-
tween both methods. With the usual care (RMI) 83 % of
all adnexal masses are diagnosed correctly, versus 96 %
with simple rules. The consequences of the difference in
correct diagnosed patients between the various test are
recharged in the treatment (costs of surgical manage-
ment and hospital stay following surgery) and will there-
fore lead to a difference in cost-effectiveness.
Discussion
Currently the RMI is the most frequently used method
to distinguish benign from malignant adnexal masses.
However, because of its low sensitivity (75–80 %), malig-
nant tumors will be wrongfully diagnosed as benign in a
substantial amount of cases. Subjecting these patients to
a laparoscopy can induce spill of cyst fluid, which will
deteriorate the prognosis of the patient [27].
The aim of this study is to compare the diagnostic ac-
curacy of different diagnostic methods for differentiating
benign from malignant adnexal masses. We will test the
hypothesis that a two-step triage test consisting of sim-
ple rules, if necessary followed by subjective assessment
or MRI, will have better diagnostic accuracy than the
RMI and therefore will improve the management of
women with adnexal masses. Furthermore, a more cor-
rect diagnosis will avoid unnecessary costs due to in-
appropriate or repeat operations. However, unacceptable
high costs due to the use of multiple technical examina-
tions should also be avoided. Therefore, we will also
examine the cost-effectiveness of changing the diagnos-
tic procedure.
Indirect, we hope to achieve a decrease in peri-
operative morbidity and increase of quality of life by
diminishing overtreatment, and also an increase in five-
year disease-free and overall survival due to improved
referral to a gynecological oncologist. However, this
study is not powered for these analyses. As such, we will
not be able to draw any conclusions with regards to
these endpoints.
This study would be the first study that investigates
the role of simple rules as a triage test in a geographic
referral system. When the hypothesis is confirmed, the
results of this study could have major effects on current
guidelines and implementation of the triage test in daily
clinical practice could be possible. Hospitals will be able
to use either simple rules in combination with subjective
assessment or in combination with MRI, depending on
the expertise present and the sources available in each
hospital or region.
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